Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2021 - 2026)
Xilio Therapeutics' (XLO) quarterly Gains from Sales and Divestitures came in at $7952.0 in Q1 2026, down 92.86% year-on-year from $111375.0 in Q1 2025, and little changed quarter-over-quarter from $7952.0 in Q4 2025.
Xilio Therapeutics (XLO) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Xilio Therapeutics has disclosed Gains from Sales and Divestitures across 6 years of filings, most recently posting $7952.0 for Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $7952.0, down 92.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $7952.0 (down 92.86% YoY), and the FY2025 annual result was $7952.0, up 41.57% from the prior year.
- Gains from Sales and Divestitures came in at $7952.0 for Q1 2026 at Xilio Therapeutics, roughly flat from $7952.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $111375.0 in Q1 2025 to a low of $4777.0 in Q1 2024.
- The 5-year median for Gains from Sales and Divestitures is $24195.0 (2023), against an average of $37522.8.
- Across the five-year window, Gains from Sales and Divestitures jumped 2231.48% in 2025 and plunged 92.86% in 2026, its largest moves.
- Xilio Therapeutics' Gains from Sales and Divestitures stood at $64415.0 in 2022, then plunged by 39.07% to $39250.0 in 2023, then slumped by 85.69% to $5617.0 in 2024, then soared by 41.57% to $7952.0 in 2025, then changed by 0.0% to $7952.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $7952.0 (Q1 2026), $7952.0 (Q4 2025), and $111375.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xilio Therapeutics | 144.35 Mn | -5.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,952.00 |
| Mar 31, 2026 | 7,952.00 |
| Dec 31, 2025 | 7,952.00 |
| Dec 31, 2025 | 7,952.00 |
| Sep 30, 2025 | 111,375.00 |
| Sep 30, 2025 | 111,375.00 |
| Jun 30, 2025 | 111,375.00 |
| Jun 30, 2025 | 111,375.00 |
| Mar 31, 2025 | 111,375.00 |
| Mar 31, 2025 | 111,375.00 |
| Dec 31, 2024 | 5,617.00 |
| Dec 31, 2024 | 5,617.00 |
| Sep 30, 2024 | 5,617.00 |
| Sep 30, 2024 | 5,617.00 |
| Jun 30, 2024 | 5,617.00 |
| Jun 30, 2024 | 5,617.00 |
| Mar 31, 2024 | 4,777.00 |
| Mar 31, 2024 | 4,777.00 |
| Dec 31, 2023 | 39,250.00 |
| Dec 31, 2023 | 39,250.00 |